CANCER EPIDEMIOLOGY, PREVENTION & CONTROL (CEPC) The mission of the Cancer Epidemiology, Prevention & Control (CEPC) Program is to reduce the population burden of cancer through the generation of knowledge of factors that contribute to cancer incidence, morbidity, and mortality, and the development of effective, and as needed, tailored primary, secondary, and tertiary cancer prevention strategies. To accomplish this mission, our faculty conduct clinical and community-based studies in the general population, as well as in targeted and underserved populations. Program Leadership includes Drs. Kathleen Malone and Marian Neuhouser as Co-Leaders and Drs. Margaret ?Peggy? Hannon and Scott Ramsey as Associate Program Leaders. CEPC has 84 members from 21 departments across the Consortium, representing multiple scientific disciplines including epidemiology, health services, health economics, health outcomes, behavioral sciences, medical oncology, nutrition, psychology, and genetics. Thirty-six members have primary appointments at the Fred Hutch, 47 have primary appointments at University of Washington, and 1 has a primary appointment at Seattle Children's. Twenty-eight members joined CEPC in this grant period. In FY 2018, CEPC had $27.5M (direct costs) in research funding, of which $17.4M (63.3%) is peer-reviewed, including $10.6M from NCI. In addition, CEPC is the home of several large coordinating centers (not counted in research funding) which are associated with an additional $9.3M in funding. CEPC program members published 1,871 papers in this grant period of which 23% reflected intra-programmatic collaborations, 28% reflected inter-programmatic collaborations, and 50% reflected external collaborations. Eleven of 12 Consortium Shared Resources were utilized by CEPC members in the course of their work over the last cycle. This P30 grant assists this program by providing administrative and logistical support for CEPC meetings, pilot funding for new research projects, and recruitment resources for new faculty. Key program resources include: the Cancer Surveillance System (CSS), our SEER Cancer Registry; the Hutchinson Institute for Cancer Outcomes Research (HICOR); the UW Health Promotion Research Center (HPRC); the Institute for Health Metrics and Evaluation (IHME); large well-characterized cohorts with extensive data and biospecimens; national coordinating centers; and nationally-recognized cancer expertise that spans the cancer control continuum. CEPC plays an important role in training the next generation of cancer researchers. The CEPC research portfolio is focused on populations, problems, and inequities in our catchment area and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853660
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications